Prosecution Insights
Last updated: October 25, 2026
Application No. 17/795,995

SCREENING CULTURE MEDIUM AND SCREENING METHOD

Final Rejection §101§103§112
Filed
Jul 28, 2022
Priority
Feb 05, 2020 — JP 2020-017999 +1 more
Examiner
AFREMOVA, VERA
Art Unit
1653
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Teikyo University
OA Round
4 (Final)
50%
Grant Probability
Moderate
5-6
OA Rounds
0m
Est. Remaining
80%
With Interview

Examiner Intelligence

Grants 50% of resolved cases
50%
Career Allowance Rate
447 granted / 886 resolved
-9.5% vs TC avg
Strong +29% interview lift
Without
With
+29.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 7m
Avg Prosecution
47 currently pending
Career history
957
Total Applications
across all art units

Statute-Specific Performance

§101
8.0%
-32.0% vs TC avg
§103
45.9%
+5.9% vs TC avg
§102
18.9%
-21.1% vs TC avg
§112
21.7%
-18.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 886 resolved cases

Office Action

§101 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of claims Claims 1-5 and 7-18 as amended on 7/17/2026 are pending. Claims 7-17 were been withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to nonelected invention(s), there being no allowable generic or linking claim. Applicant timely traversed the restriction requirement in the reply filed on 4/30/2025. Claims 1-5 and 18 as amended on 7/17/2026 are under examination in the instant office action. Claim Rejections - 35 USC § 112 Indefinite Claims 1-5 and 18 as amended remain rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 remains indefinite with respect to claim-recited phrase “chromophores that are capable of undergoing a coupling reaction” in the lack of specific definitions and examples as intended for the instant claims. The specification example for determination of substrate utilization by yeast is not based in the use of chromogenic substrates but on turbidity detention. Thus, claim is indefinite because it is unclear what is intended for claim-recited chromophores. Written description Claims 1-5 and 18 as amended remain rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. The nature of the invention relates to a screening method for identification of Candida auris as based on positive ability to degrade raffinose and negative ability to degrade xylose (par. 0051 of published application US 2023/0077422). Claim 1 recites that a screening culture medium comprises raffinose and xylose as 2 enzyme substrates, that there is a chromogen which is covalently linked to each enzyme substrate and that the chromogen used for raffinose is different from a chromogen used for xylose. Claim 18 further recites that chromogen is indoxyl derivative. The as-filed specification does not describe compounds that would be a raffinose covalently linked to a chromogen and a xylose covalently linked to a chromogen. The as-filed specification does not describe compounds that would be a raffinose covalently linked to indoxyl and a xylose covalently linked to indoxyl. Although the generic description in the as-filed specification refers to the use of a generic indoxyl chromogen for labeling a generic enzyme substrate as intended to detect color upon hydrolysis of labeled enzyme substrate by a microbial enzyme, there are no description of a raffinose covalently linked to indoxyl and a xylose covalently linked to indoxyl. Although labeling of microbial enzyme substrates with chromogens is known in the art (see below the cited reference by Orenga), there is no description in the as-filed specification of a raffinose covalently linked to any chromogen and a xylose covalently linked to any chromogen including raffinose covalently linked to indoxyl and xylose covalently linked to indoxyl. Particular embodiment (par. 0077-0079) describes the use of a prior art medium kit, wherein raffinose and xylose are present separately in different cups (see par. 0079, line 4), wherein raffinose and xylose are not labeled by any chromogens, and wherein degradation of raffinose, xylose and other substrates determined by development of turbidity (opacity) but not by color or different colors resulting from microbial hydrolysis. Thus, the claimed subject matter is not properly described in the application as filed. The claimed concept of the use of a screening culture medium comprising raffinose and xylose as 2 enzyme substrates, wherein raffinose and xylose are each labeled by a covalently linked chromogen, wherein the chromogen used for raffinose is different from a chromogen used for xylose is not satisfactorily resolved as disclosed in the as-filed specification. Consequently, there is a reasonable doubt as to possession of the claimed invention at the time of filing. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 1-5 and 18 as amended remain rejected under 35 U.S.C. 101 because the claimed invention is directed to a product of nature without significantly more. Claims 1-5 recite a composition comprising nutrient compounds including raffinose and xylose, and further N-acetylglucosamine, potassium gluconate, glycerol and/or glucosamine. All claim-recited compounds are natural compounds. With regard to claim-recited limitations drawn to label, color and chromophores, that might develop or not upon potential degradation of nutrients, it is noted that the claim-recited terms are genetic and they fail to point out any specific characteristics that would distinguish labels or chromophores from natural compounds. The indoxyl and its derivatives recited in the claim 18 are found in nature and derived from plants like Isatis tinctoria or a plant glycoside called indican. Thus, the final composition is a simple combination of natural products. This judicial exception is not integrated into a practical application because claimed elements in combination do not add a meaningful limitation or extra-solution to the claimed product, and the claimed product as a whole is nothing more than an attempt to generally link the product of nature to a particular technological environment. The claim does not include additional elements that are sufficient to amount to significantly more than the judicial exception because when considered separately and in combination, they do not add significantly more (also known as an “inventive concept”) to the exception. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1-5 and 18 as amended remain rejected under 35 U.S.C. 103 as being unpatentable over BioMerieux ID 32C identification system (IDS reference; BioMerieux “ID 32 C identification system for yeasts”. 2011/07, pages 1-9), US 4,450,238 (Vitobello et al) and Orenga et al (“Enzymatic substrates in microbiology”. Journal of Microbiological Methods. 2009, 79, pages 139-155). The BioMerieux “ID 32 C identification system for yeasts” is a composition comprising a medium with carbohydrate substrates for potential assimilation by yeasts as intended for identification of various species of yeasts. The medium comprises raffinose, xylose, N-acetylglucosamine, potassium gluconate, glycerol and glucosamine (see table on page 1). The assimilation or degradation of each substrate is detected by a change in turbidity or opacity (page 2, col. 2). Thus, the cited medium as disclosed is lacking a reagent or a label based on indoxyl that would manifest a color change when carbohydrate substrate is degraded. However, it is a common microbiological practice to incorporate a reagent or a label that would manifest a color change when carbohydrate substrate is degraded. For example, as applied to the claim-recited raffinose, it is well known that raffinose is hydrolyzed by alpha-galactosidase of yeasts including Saccharomyces cerevisiae (see abstract of US 4,450,238) and alpha-galactosidase substrate is commonly labeled with indoxyl (see table 2, line1, on page 145 of the reference by Orenga) for enzymatic tests and applications related to yeasts (YS) in commercial ID products (see table 3 on page 146 of the reference by Orenga) that are similar, if not the same, to the BioMerieux ID identification system discussed above. Therefore, it would have been obvious to one having ordinary skill in the art at the time the claimed invention was filed to incorporate the enzyme-substrate associated labels/chromophores including indoxyl derivatives into the BioMerieux yeast identification product with a reasonably expectation in success for detecting developing colors upon enzymatic degradation of substrates because it is a common knowledge and routine practice in microbiological applications as evidenced by Orenga. Thus, the claimed invention as a whole was clearly prima facie obvious, especially in the absence of evidence to the contrary. The claimed subject matter fails to patentably distinguish over the state art as represented be the cited references. Therefore, the claims are properly rejected under 35 USC § 103. With respect to limitation drawn to xylose, or to a potentially different label or color for xylose digestion, it is noted that pentose carbohydrates as xylose are not readily fermented by yeasts, for example: Saccharomyces cerevisiae (see page 2 at it. 3 by reference by Moyses). In the instant application xylose is not degraded by none of the yeasts of interest (see table 10 of as-filed specification) and no labels is disclosed for the claimed enzymatic substrates. Response to Arguments Applicant's arguments filed on 7/17/2026 have been fully considered but they are not found persuasive. With regard to claim rejection under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph (as being indefinite), Applicants presented no argument or clarification about claim-recited phrase “chromophores that are capable of undergoing a coupling reaction” beyond a generic reference to a generic specification description. However, a definite claim should particularly point out what Applicant regards as the invention. If the phrase “chromophores that are capable of undergoing a coupling reaction” refers to a common mechanism of a generic use of a generic chromophore, then there is a reasonable doubt as what is intended for the claim as an invention. Why is it recited in the claim? With regard to claim rejection under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, (written description requirement), Applicants appear to argue that it is obvious to use chromogenic substrates and that the skilled person can select the substrate associated labels (response pages 11-12). This argument is not found persuasive because this is a matter of written description, not a question of what one of skill in the art would or would not have known. The material within the four corners of the as-filed specification must lead to the claim-recited concept and/or limitation. With regard to claim rejection under 35 U.S.C. 101 Applicants argue that the claimed product is not a simple combination of natural products because claim-recited combination performs a new function (response page 13, par. 2). This argument is not found persuasive because it is a generic statement. No specific new function is described in the specification example which is solely based on detection of turbidity but not on color development. The substrates raffinose and xylose are natural products and they are also known microbials substrates. The indoxyl and its derivatives recited in the pending claim 18 are found in nature and derived from plants like Isatis tinctoria or a plant glycoside called indican. With regard to the claim rejection under 35 USC § 103 Applicants’ arguments are drawn/based on a screening method for identification of yeast Candida auris as based on positive ability to degrade raffinose and negative ability to degrade xylose. In particular, with regard to primary reference by BioMerieux Applicants also argue that database of the cited BioMerieux system does not comprises information about detection of Candida auris (response pages 17-18). However, the claimed invention is a composition matter or a culture medium with raffinose and xylose but not a method of using the medium for detection of Candida auris. The cited BioMerieux “ID 32 C identification system for yeasts” is a composition comprising enzyme substrates including raffinose and xylose. Thus, it is a composition of matter with raffinose and xylose as required by the claims. In the cited medium system the detection of positive or negative degradation of raffinose and/or xylose is possible/done by development of turbidity which would be a visible change in a generic color from clear to opaque upon enzymatic degradation of enzymatic substrate. The cited BioMerieux medium does not comprise chromogens for detection of bright color changes. However, modifications of enzymatic substrates with chromogens for detection of bright color changes upon microbial enzymatic digestion of chromogenic enzymatic substrates have been known and used in the art of microbiology as clearly taught by the cited reference by Orenga. In particular, degradation of raffinose by yeasts is possible due to activity of enzyme alpha-galactosidase (abstract of US 4,450,238). The alpha-galactosidase substrates are commonly labeled with indoxyl (see table 2, line 1, on page 145 of the reference by Orenga) for enzymatic tests and applications related to yeasts (YS) in commercial ID products (see table 3 on page 146 of the reference by Orenga) that are similar, if not the same, to the BioMerieux ID identification system discussed above. Therefore, chromogenic modifications of enzymatic substrates are known and obvious to one of ordinary skill in the art. Now turning to the claimed invention, the claimed subject matter is not properly described in the application as filed because there is no disclosure of chemical compounds that would be raffinose and/or xylose being each labeled by a covalently linked chromogen as recited in the claims. The disclosed detection medium does not comprise any chromogens for any substrates. Thus, in the absence of evidence to the contrary as based on applicants’ disclosure, the claimed invention as a whole is considered as clearly prima facie obvious because prior art clearly teaches and suggests chromogenic modifications of yeast alpha-glucosidase enzymatic substrates with indoxyl derivatives and because yeast alpha-glucosidase enzyme has ability to digest claimed raffinose. No claims are allowed. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to VERA AFREMOVA whose telephone number is (571)272-0914. The examiner can normally be reached Monday-Friday: 8.30am-5pm EST. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sharmila Landau can be reached at (571) 272-0614. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Vera Afremova October 5, 2026 /VERA AFREMOVA/ Primary Examiner, Art Unit 1653
Read full office action

Prosecution Timeline

Show 2 earlier events
Aug 06, 2025
Response Filed
Nov 25, 2025
Final Rejection mailed — §101, §103, §112
Feb 25, 2026
Response after Non-Final Action
Mar 24, 2026
Request for Continued Examination
Mar 25, 2026
Response after Non-Final Action
Apr 20, 2026
Non-Final Rejection mailed — §101, §103, §112
Jul 17, 2026
Response Filed
Oct 07, 2026
Final Rejection mailed — §101, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12766172
COMPOSITION FOR PREVENTING, TREATING, OR IMPROVING GASTROINTESTINAL DISEASES COMPRISING STRAIN OF GENUS CORYNEBACTERIUM AND CULTURE THEREOF
4y 10m to grant Granted Oct 20, 2026
Patent 12747444
Heterotrophic Production Methods for Microbial Biomass and Bioproducts
5y 6m to grant Granted Sep 29, 2026
Patent 12721871
PROBIOTICS FOR THE PREVENTION OR TREATMENT OF VIRAL RESPIRATORY INFECTIONS
1y 10m to grant Granted Sep 01, 2026
Patent 12708650
Recombinant Bacteria And Uses Thereof
4y 11m to grant Granted Aug 18, 2026
Patent 12702637
TOPICAL COSMETIC COMPOSITION, USE OF THE COMPOSITION AND TONIC FOR FACIAL APPLICATION
4y 6m to grant Granted Aug 11, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
50%
Grant Probability
80%
With Interview (+29.4%)
3y 7m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 886 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month